Jackson Financial Inc. current report, 09 May 2022

Jackson Financial Inc. Form 8-K Summary

Business Context and Reporting Period

Jackson Financial Inc. filed a Form 8-K reporting its first-quarter 2022 results and a quarterly dividend authorization. The reported period ended March 31, 2022. The filing date is May 10, 2022, although the report identifies May 9, 2022 as the earliest event date.

Financial Results and Key Metrics

The filing announces that the company issued a press release covering financial results for the quarter ended March 31, 2022. The text provided does not include the press release contents or clear values for revenue, net income, adjusted earnings, cash flow, margins, assets, debt, liquidity, capital, or other financial metrics.

Material Changes Versus Prior Period

The filing text does not provide a clear comparison with the prior-year or prior-quarter period. Any changes in operating or financial performance would be contained in Exhibit 99.1, which is referenced but not included in the provided text.

Dividend, Outlook, and Risks

  • The board approved a second-quarter cash dividend of $0.55 per Class A common share.
  • The dividend is payable June 16, 2022 to shareholders of record at the close of business on June 2, 2022.
  • The filing contains customary forward-looking statement disclosures, noting that projections and expectations are subject to assumptions, risks, and uncertainties that could cause actual results to differ materially.
  • The filing does not provide specific management guidance, operating outlook, contingencies, or unusual items in the supplied text.

Most Important Facts to Verify

  • Review Exhibit 99.1 for first-quarter revenue, earnings, adjusted operating results, cash flow, capital, liquidity, and year-over-year comparisons.
  • Confirm the company’s definitions and reconciliations for any non-GAAP measures included in the earnings release.
  • Verify the dividend record date, payment date, and per-share amount of $0.55.
  • Review the company’s SEC filings for detailed risk factors and any factors affecting future results.